Drug Trial Radar · NCT04608318
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
897
Planned (sponsor's estimate)
Start
Mar 1, 2021
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- German CLL Study GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Stichting Hemato-Oncologie voor Volwassenen Nederland; Nordic CLL Study Group; Swiss Group for Clinical Cancer Research (SAKK); Cancer Trials Ireland; Gruppo Italiano Malattie EMatologiche dell'Adulto; Grupo Español de Leucemia Linfocítica Crónica (GELLC); The Israeli CLL Study Group (ICLLSG); Janssen Pharmaceutica N.V., Belgium; AbbVie; Hoffmann-La Roche
- First posted
- Oct 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax by measuring progression-free survival (PFS) in patients with previously untreated CLL.
Conditions
- Chronic Lymphoid Leukemia
Interventions
IbrutinibBiological
Cycles 1 - X: 420 mg daily, d1-28 p.o.
VenetoclaxBiological
Arm VG Cycle 1: 20 mg (2 tabl. at 10 mg), d22-28 p.o. Cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28 p.o. Cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28 p.o. Arm VI Cycle 4: 20 mg (2 tabl. at 10 mg), d1-7; 50 mg (1 tabl. at 50 mg), d8-14; 100 mg (1 tabl. at 100 mg), d15-21; 200 mg (2 tabl. at 100 mg), d22-28 p.o. Cycles 5-15: 400 mg (4 tabl. at 100 mg), d1-28 p.o.
ObinutuzumabBiological
Cycle 1: (100 mg, d1 + 900 mg, d2) or 1000 mg, d1; 1000 mg, d8 + d15 i.v. Cycle 2 - 6: 1000 mg, d1 i.v.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator-assessed progression-free survival (PFS)Time frame: Up to 80 month
Locations
181 sites in 13 countries. Site status is shown where the registry gives one.
LKH-Universtitätsklinikum Graz
Graz, Austria
Landeskrankenhaus - Universitätskliniken Innsbruck
Innsbruck, Austria
Medizinische Universität Wien
Vienna, Austria
Hanusch Krankenhaus
Vienna, Austria
Wiener Gesundheitsverbund Klinik Ottakring
Vienna, Austria
Algemeen Ziekenhuis St. Jan
Bruges, Belgium
Universitair Ziekenhuis Leuven
Leuven, Belgium
Algemeen Ziekenhuis Delta
Roeselare, Belgium
Aalborg Universitetshospital
Aalborg, Denmark
Aarhus Universitetshospital
Aarhus, Denmark
Rigshospitalet
Copenhagen, Denmark
Sydvestjysk Sygehus Esbjerg
Esbjerg, Denmark
Regionshospitalet Holstebro
Holstebro, Denmark
Odense Universitetshospital
Odense, Denmark
Zealand University Hospital
Roskilde, Denmark
Lillebaelt Vejle Sygehus
Vejle, Denmark
Helsinki University Hospital
Helsinki, Finland
Tampere University Hospital
Tampere, Finland
Turku University Hospital
Turku, Finland
Universitätsklinikum Augsburg
Augsburg, Germany
Onkologische Schwerpunktpraxis Kurfürstendamm
Berlin, Germany
Charite Universitaetsmedizin - Campus Benjamin Franklin
Berlin, Germany
Helios Klinikum Berlin Buch
Berlin, Germany
Charite Universitätsmedizin - Campus Virchow Klinikum
Berlin, Germany
Ev. Diakoniekrankenhaus
Bremen, Germany
Universitätsklinik Köln
Cologne, Germany
Gemeinschaftspraxis für Hämatologie & Onkologie
Dortmund, Germany
Gemeinschaftspraxis Hämatologie Onkologie
Dresden, Germany
Universitätsklinik Carl Gustav Carus
Dresden, Germany
Sana Krankenhaus Benrath
Düsseldorf, Germany
St. Georg Klinikum Eisenach
Eisenach, Germany
ISP Erlangen Onkologische Schwerpunktpraxis
Erlangen, Germany
Universitätsklinikum Erlangen
Erlangen, Germany
Universitaetsklinikum Essen
Essen, Germany
Onkologische Schwerpunktpraxis
Esslingen am Neckar, Germany
Centrum für Hämatologie und Onkologie Bethanien
Frankfurt, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Uniklinikum Gießen und Marburg
Giessen, Germany
MVZ Onkologische Kooperation Harz
Goslar, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Showing 40 of 181 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.